{"entity":{"id":"rigel-pharmaceuticals","kind":"company","name":"Rigel Pharmaceuticals","aka":[],"tldr":"Commercialises olutasidenib (Rezlidhia), an IDH1 inhibitor for relapsed AML, alongside fostamatinib.","summary":"Rigel Pharmaceuticals, based in South San Francisco and listed as RIGL, commercialises olutasidenib, sold as Rezlidhia, an IDH1 inhibitor for relapsed acute myeloid leukaemia, alongside fostamatinib. Olutasidenib was approved on 1 December 2022 for relapsed or refractory IDH1-mutated AML, and Rigel licensed it from Forma Therapeutics, later part of Novo Nordisk, in 2022. OnCo links it to acute myeloid leukaemia and to the olutasidenib drug record. Whether a second IDH1 inhibitor can take share from the first on durability or tolerability is the open question for a company that did not discover the drug it sells. Olutasidenib has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.rigel.com"}],"tags":[],"related":[],"cancers":["aml"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["olutasidenib","fostamatinib","pralsetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06161974","nct05308264"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.rigel.com","ticker":"RIGL","investors":[],"funding":[]},"route":"/companies/rigel-pharmaceuticals/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"fostamatinib","kind":"drug","name":"Fostamatinib","route":"/drugs/fostamatinib/"},{"id":"olutasidenib","kind":"drug","name":"Olutasidenib","route":"/drugs/olutasidenib/"},{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/"}],"trial":[{"id":"nct06161974","kind":"trial","name":"Study of Olutasidenib and Temozolomide in HGG","route":"/trials/nct06161974/"},{"id":"nct05308264","kind":"trial","name":"Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)","route":"/trials/nct05308264/"}]}}